Plain-English translation of NCT07222488 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This clinical trial is testing a new medication called to treat high-risk non-muscle invasive bladder cancer in people who have already undergone surgery to remove their tumor. Researchers want to learn whether this medication is safe and well-tolerated when given directly into the bladder. The goal is to see if this treatment can help prevent the cancer from coming back.
Bladder cancer that has not spread to the muscle layer is typically treated with surgery followed by additional therapy. However, current standard treatments don't work for everyone, and some people's cancer returns despite treatment. This trial is exploring whether this new medication could be a better option, especially for people who haven't responded well to or have already been treated with traditional therapies.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive the medication once a week for the first 6 weeks, then once a month for 9 months—a total of about 15 months of treatment. The medication is delivered directly into your bladder through a catheter (a thin tube). You will have regular visits to monitor your safety, check your bladder, and watch for any side effects. The study will involve blood tests, urine tests, and bladder scans to track how well the treatment is working.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States
Austria
Belgium
Canada